Evaluation of Venezuelan Equine Encephalitis (VEE) replicon-based Outer surface protein A (OspA) vaccines in a tick challenge mouse model of Lyme disease

Vaccine

Volumn 21, Issue 25-26, 2003, Pages 3875-3884

  Gipson, Clay L ^a   Davis, Nancy L ^a   Johnston, Robert E ^a   De Silva, Aravinda M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Outer surface protein A; Vaccine; Venezuelan Equine Encephalitis; Virus replicon particles

Indexed keywords

ALUMINUM POTASSIUM SULFATE; BACTERIAL VACCINE; FREUND ADJUVANT; OUTER SURFACE PROTEIN A VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENETIC CODE; IMMUNE RESPONSE; IMMUNOGENICITY; INFESTATION; IXODES SCAPULARIS; LYME DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPLICON; TH1 CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VIRAL GENE DELIVERY SYSTEM;

EID: 0242380637     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00307-4     Document Type: Article

References (31)

1. Steere A.C. Lyme disease. N. Engl. J. Med. 321(9):1989;586-596.
2. Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1999;48(RR-7):1-17, 21-15.
3. Ohnishi J., Piesman J., de Silva A.M. Antigenic and genetic heterogeneity of Borrelia burgdorferi populations transmitted by ticks. Proc. Natl. Acad. Sci. U.S.A. 98(2):2001;670-675.
4. de Silva A.M., Zeidner N.S., Zhang Y., Dolan M.C., Piesman J., Fikrig E. Influence of outer surface protein A antibody on Borrelia burgdorferi within feeding ticks. Infect Immun. 67(1):1999;30-35.
5. de Silva A.M., Telford S.R. III, Brunet L.R., Barthold S.W., Fikrig E. Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine. J. Exp. Med. 183(1):1996;271-275.
6. Steere A.C., Sikand V.K., Meurice F.et al. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group. N. Engl. J. Med. 339(4):1998;209-215.
7. Fikrig E., Barthold S.W., Kantor F.S., Flavell R.A. Protection of mice against the Lyme disease agent by immunizing with recombinant OspA. Science. 250(4980):1990;553-556.
8. Mendoza-Vega O., Keppi E., Bouchon B., Nguyen M., Achstetter T. Recombinant outer-surface protein A (des-Cys1-OspA) from the Lyme disease spirochete Borrelia burgdorferi: high production levels in Saccharomyces cerevisiae yeast cultures. Appl. Microbiol. Biotechnol. 44(5):1996;624-628.
9. Langermann S., Palaszynski S., Sadziene A., Stover C.K., Koenig S. Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi. Nature. 372(6506):1994;552-555.
10. Luke C.J., Carner K., Liang X., Barbour A.G. An OspA-based DNA vaccine protects mice against infection with Borrelia burgdorferi. J. Infect Dis. 175(1):1997;91-97.
11. Zhong W., Wiesmuller K.H., Kramer M.D., Wallich R., Simon M.M. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo. Eur. J. Immunol. 26(11):1996;2749-2757.
12. Wallich R., Siebers A., Jahraus O., Brenner C., Stehle T., Simon M.M. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but not for resolution of Lyme disease. Infect Immun. 69(4):2001;2130-2136.
13. Pushko P., Parker M., Ludwig G.V., Davis N.L., Johnston R.E., Smith J.F. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology. 239(2):1997;389-401.
14. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., Huang H.V. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science. 243(4895):1989;1188-1191.
15. Liljestrom P., Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (NY). 9(12):1991;1356-1361.
16. MacDonald G.H., Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74(2):2000;914-922.
17. Davis N.L., Brown K.W., Johnston R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70(6):1996;3781-3787.
18. Walton TE, Grayson MA. Venezuelan equine encephalomyelitis. In: TP, M (Ed.), The arboviruses: epidemiology and ecology. Boca Raton (FL): CRC Press; 1989. p. 203-32.
19. Venezuelan equine encephalitis - Colombia, 1995. MMWR Morb Mortal Wkly Rep 1995;44(39):721-4.
20. Update: Venezuelan equine encephalitis - Colombia, 1995. MMWR Morb Mortal Wkly Rep 1995;44(41):775-7.
21. Hevey M., Negley D., Pushko P., Smith J., Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology. 251(1):1998;28-37.
22. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J. Virol. 75(23):2001;11677-11685.
23. Hanson M.S., Cassatt D.R., Guo B.P.et al. Active and passive immunity against Borrelia burgdorferi decorin binding protein A (DbpA) protects against infection. Infect Immun. 66(5):1998;2143-2153.
24. Hagman K.E., Yang X., Wikel S.K.et al. Decorin-binding protein A (DbpA) of Borrelia burgdorferi is not protective when immunized mice are challenged via tick infestation and correlates with the lack of DbpA expression by B. burgdorferi in ticks. Infect Immun. 68(8):2000;4759-4764.
25. Balasuriya U.B., Heidner H.W., Hedges J.F.et al. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J. Virol. 74(22):2000;10623-10630.
26. Telford S.R. III, Fikrig E., Barthold S.W., Brunet L.R., Spielman A., Flavell R.A. Protection against antigenically variable Borrelia burgdorferi conferred by recombinant vaccines. J. Exp. Med. 178(2):1993;755-758.
27. Probert W.S., Crawford M., Cadiz R.B., LeFebvre R.B. Immunization with outer surface protein (Osp) A, but not OspC, provides cross-protection of mice challenged with North American isolates of Borrelia burgdorferi. J. Infect Dis. 175(2):1997;400-405.
28. Caley I.J., Betts M.R., Irlbeck D.M.et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71(4):1997;3031-3038.
29. Manoury B., Hewitt E.W., Morrice N., Dando P.M., Barrett A.J., Watts C. An asparaginyl endopeptidase processes a microbial antigen for class II MHC presentation. Nature. 396(6712):1998;695-699.
30. Gross D.M., Forsthuber T., Tary-Lehmann M.et al. Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis. Science. 281(5377):1998;703-706.
31. Jain VK. Recombinant OspA vaccine: assessment four years after FDA approval. In: Proceedings of the IX International Conference on Lyme Borreliosis and Other Tick-Borne Diseases, New York; 2002.